Background: Radiofrequency Echographic Multi Spectrometry (REMS) is the first clinically available approach for direct non-ionizing measurement of bone mineral density (BMD) at lumbar spine (LS) and femoral neck (FN). Available scientific evidences describe BMD estimated by REMS as an accurate parameter for the diagnosis of osteoporosis [1].

Objectives: To investigate the effectiveness of the T-score values provided by REMS scans at FN and LS in the identification of frail patients at risk for osteoporotic fractures and to compare the performance of REMS with the dual-energy X-ray absorptiometry (DXA) one.

Methods: The patients underwent DXA and REMS scans at FN and at LS. Five clusters of fractures occurred during a median 3.5-year follow-up were identified whether involving the upper limb (forearm, elbow, humerus, wrist, hand), lower limb (tibia, ankle, metatarsus), thorax (shoulder blade, shoulder, rib), hip (femur or pelvis bones), or vertebrae. The ability of REMS and DXA T-score values to assess the incidence and site of fractures was evaluated through an analysis of covariance.

Results: Seven hundred twenty-one Caucasian women were enrolled. Ninety-five fractures occurred, in particular 41 at upper limb, 16 at hip, 15 at thorax, 45 at lower limb, and 9 at vertebrae. Patients characteristics are reported in Table 1. Considering subcategories of fractured patients, there were not statistically significant differences for age, height, weight, and BMI.

In the analysis of covariance including age and BMI as covariates, the difference of T-score values between fractured and non-fractured patients is statistically significant for REMS and DXA at both sites. Lower FN T-score values were found for patients with fractures at hip or vertebra with respect to non-fractured patients both for REMS and DXA (p<0.001). Considering LS T-score, lower values were found for patients with fractures at hip, vertebra or upper limb with respect to non-fractured patients both for REMS and DXA (p<0.001, Figure).

Conclusion: REMS T-score measured at axial sites is an effective parameter for identification of patients at the risk of incident fragility fractures, in particular occurring at hip, vertebra or upper limb in a population-based sample of female subjects.

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.5343

Table 1. Baseline patient characteristics, expressed as median (25th – 75th percentiles).

<table>
<thead>
<tr>
<th></th>
<th>Patients with incident fragility fracture</th>
<th>Patients without incident fragility fracture</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age [years]</td>
<td>70 (60-73)</td>
<td>59 (54-64)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Height [cm]</td>
<td>159 (155-164)</td>
<td>160 (156-165)</td>
<td>0.08</td>
</tr>
<tr>
<td>Weight [kg]</td>
<td>63 (58-70)</td>
<td>62 (57-69)</td>
<td>0.42</td>
</tr>
<tr>
<td>BMI [kg/m²]</td>
<td>24.97 (23.13-26.86)</td>
<td>24.24 (22.22-26.59)</td>
<td>0.04</td>
</tr>
<tr>
<td>FN REMS T-score</td>
<td>-2.3 (-2.8 – -1.7)</td>
<td>-1.8 (-2.3 – -1.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FN DXA T-score</td>
<td>-2.2 (-2.8 – -1.6)</td>
<td>-1.7 (-2.3 – -1.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LS REMS T-score</td>
<td>-3.0 (-3.5 – -2.0)</td>
<td>-2.0 (-2.8 – -1.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LS DXA T-score</td>
<td>-2.8 (-3.4 – -1.8)</td>
<td>-1.9 (-2.7 – -1.0)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

* Wilcoxon ranksum test

Figure. Boxplot of the distribution of T-score values estimated REMS and DXA at FN and LS among patients without incident fragility fracture and patients with incident fragility fractures at different sites.


Disclosure of Interests: Giovanni Adami: None declared, Giovanni Arioli §: None declared, Gerolamo Bianchi Grant/research support from: Celgene, Consultant of: Amgen, Janssen, Merck Sharp & Dohme, Novartis, UCS, Speakers bureau: Abizie, Abiogen, Afta-Sigma, Amgen, BMS, Celgene, Chiesi, Eli Lilly, GSK, Janssen, Medac, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi Genzyme, Servier, UCB, Maria Luisa Brandi: None declared, Carla Caffarelli: None declared, Luisella Cianferotti: None declared, Giuseppina Girasole: None declared, Stefano Gonnelli: None declared, Monica Manfredini: None declared, Maurizio Muratore: None declared, Eugenio Quarta: None declared, Laura Quarta: None declared. Davide Gatti Speakers bureau: Davide Gatti reports personal fees from Abiogen, Amgen, Janssen-Cilag, Mundipharma, outside the submitted work.

DOI: 10.1136/annrheumdis-2020-eular.5359
Methods: We have retrospectively analyzed the 10-year risk of major osteoporotic fracture calculated with the DeFRACalc79 tool in postmenopausal women aged over 50 years that were initiating an anti-osteoporotic treatment (fully reimbursed according to the Note 79). DeFRACalc79 is a new web-based fracture risk-assessment tool (https://defracosteoporosi.it) that algorithmically adjusts the risk based on multiple risk factors contemplated by the Note 79, which regulates the reimbursability for osteoporosis medications in Italy (Italian Agency for Drugs, AIFA), including demographic and anthropometric data, femoral and/or lumbar spine BMD T-score, family history of femoral or vertebral fractures, number and site of previous osteoporotic fracture (including vertebral, femoral, and non-vertebral non-femoral fractures), glucocorticoid treatment (> 3 or < 12 months, ≥5mg prednisone or equivalent), adjuvant hormone therapy, breast cancer, and comorbidities that induce an increased risk of fracture (rheumatoid arthritis and other connective tissue diseases, chronic obstructive pulmonary disease, inflammatory bowel diseases, Parkinson’s disease, multiple sclerosis, human immunodeficiency virus infection, diabetes, or severe physical handicap). This is a sub-analysis of the cross-sectional observational study to validate and further develop the DeFRA algorithm for the estimation of the risk of osteoporotic fractures, promoted by Verona hospital with the unconditional support of Amgen Srl.

Results: Among 208 women, 116 (55.8%) were treated with adjuvant hormone therapy for breast cancer and 92 (44.2%) were on glucocorticoid ≥5mg/day. Women on glucocorticoids had a greater mean 10-year risk of fracture compared to women on adjuvant hormone therapy for breast cancer (67.0% vs 39.1%, p<0.01). 50.7% of women on adjuvant hormone therapy for breast cancer used denosumab, 28.0% zoledronic acid and 17.3% alendronate. In glucocorticoid-induced osteoporosis, 17.6% of the women used teriparatide, 37.3% alendronate, 29.4% zoledronic acid and 13.7% denosumab.

Conclusion: In our cohort of patients, treatment with adjuvant hormone therapy for breast cancer was slightly more common than glucocorticoids. Women with glucocorticoid-induced osteoporosis had a greater risk of fracture compared to patients treated with adjuvant hormone therapy for breast cancer. Half of the patients on adjuvant hormone therapy for breast cancer were prescribed with denosumab. One-fifth of the patients with glucocorticoid-induced osteoporosis was treated with teriparatide. DeFRACalc79 is a useful and practical tool for the integrated evaluation of fracture risk in drug-induced osteoporosis.

Disclosure of Interests: Giovanni Adam: None declared, Angelo Fassio: Reports personal fees from: Abiogen and Novartis, outside the submitted work, Giovane Orsolini: None declared, Ombretta Viapiana: None declared, Davide Gatti: Speakers bureau: Angelo Fassio reports personal fees from: Abiogen, Amgen, Janssen-Cilag, Mundipharma, outside the submitted work, Maurizio Rossini: Speakers bureau: AbbVie, Abbigen, BMIS, Eli-Lilly, Novartis, Pfizer, Sanofi, Sandoz and UCB

DOI: 10.1136/annrheumdis-2020-eular.2565

SAT0457

PREVALENCE OF OSTEOPOROSIS IN OSTEOARTHRITIC PATIENTS: A SYSTEMATIC REVIEW

A. Ahmadi Pinhalahi 1, D. Kim 1, Y. Li 1, T. Varghese 1, J. Pope 2 1Western University, Medicine, London, Canada

Background: There is controversy regarding the relationship between osteoarthritis (OA) and osteoporosis (OP). While OA may be associated with increased bone mineral density (BMD) due to increased weight, evidence exists that the incidence of OP may be increased in patients with OA.

Objectives: To determine whether the prevalence of OP is increased in patients with OA, compared to age and sex-matched populations.

Methods: We conducted a systematic literature review using the databases PubMed, Embase, Scopus, and Web of Science, including articles that analyzed the frequency, rate, prevalence, incidence, risk, or excess risk of OP in patients with OA compared to age and sex-matched comparison groups (controls). Articles with fewer than 200 participants, and those without controls were excluded. Two reviewers conducted title and abstract screening.

Results: Of 2772 unique articles, 49 articles were chosen for full article screening, and 4 articles met the inclusion criteria of our present study. Data from 2 and 4 studies used OP in men and women, respectively. Other articles reported on BMD and not OP so they were excluded. In women, 998 participants with OA were compared with 1903 controls. The pooled estimate of the odds ratio for prevalence of OP vs general matched population was not statistically different (Figure 1). In men, 136 participants with OA were compared with 682 controls. The results did not show a statistically significant difference in the frequency of OP in OA in men (Figure 2).

Figure 1. Prevalence of OP in women with OA compared to controls

Figure 2. Prevalence of OP in men with OA compared to controls

Conclusion: The frequency of OP in participants with OA was the same in both men and women compared to the matched controls.

References:

Disclosure of Interests: Ali Ahmadi Pinhalahi: None declared, Dongkeun Kim: None declared, Yueyang Li: None declared, Timothy Varghese: None declared, Janet Pope Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lilly & Company, Merck, Roche, Seattle Genetics, UCB, Consultant of: AbbVie, Actelion, Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisco Sciences, Eli Lilly & Company, Emeralid, Gilead Sciences, Inc., Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB, Speakers bureau: UCB

DOI: 10.1136/annrheumdis-2020-eular.5136

SAT0465

THE POLYMORPHISM ON FAT MASS AND OBESITY ASSOCIATED GENE (FTO) WAS ASSOCIATED WITH LOW BONE MASS IN JAPANESE COMMUNITY DWELLING POPULATION.

K. Arima 1, M. Tamai 2, F. Nonaka 3, N. Iwamoto 4, S. Mizukami 5, T. Nishimura 5, Y. Abe 5, T. Oriuchi 5, K. Aoyagi 5, 1Nagasaki University Graduate School of Biomedical Sciences, Department of Public Health, Nagasaki, Japan; 5Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan; 2Nagasaki University Graduate School of Biomedical Sciences, Department of Rehabilitation Sciences, Nagasaki, Japan

Background: A polymorphism on FTO (OMIM 610966) was reported as a causal variant for obesity, plays a critical role not only in amount of adipose tissue but also in function of mitochondrial thermogenesis.

Objectives: To examine the association of the genotype on a single nucleotide polymorphism on FTO with bone health.

Methods: FTO rs1421085 polymorphism was genotyped in 1,601 community-dwelling Japanese participants. This cross-sectional study was nested in Nagasaki Islands Study, which is a prospective cohort in Goto City, in islands of Japan. Participants were recruited at medical check-ups for community dwelling population.

Bone mass of the calcaneus was evaluated with stiffness index calculated using a quantitative ultrasound measurement. Low bone mass was defined as a stiffness index less than 80% of the young adult mean.

Sera and peripheral blood mononuclear cells were obtained. The SNP of rs1421085 was genotyped using hydrolysis probe. The chi-squared test was used to determine whether the variants were in equilibrium in that population. Trend for the median of BMI among genotypes was assessed using the Jonckheere-Terpstra test. Potential associations between FTO polymorphism and low bone mass were evaluated using logistic regression. All analyses were carried out using SPSS 23.

Results: Genotype and allele frequencies for the polymorphism were in Hardy-Weinberg equilibrium (minor allele frequency 0.16, p = 0.40) in 1,601 community-dwelling persons (mean age was 68.5 years in men and 68.1 years in women).

There were significant associations between the minor allele and higher median of BMI on dose dependent manner in men (p = 0.04 for trend in men and p = 0.10...